Alternaria mycotoxins frequently contaminate agricultural crops and may impact animal and human health. However, data on mammalian metabolism and potential biomarkers of exposure for human biomonitoring (HBM) are scarce. Here, we report the preliminary investigation with respect to metabolism and excretion of Alternaria toxins in Sprague Dawley rats. Four animals were housed in metabolic cages for 24 h after gavage administration of an Alternaria alternata culture extract containing ten known toxins. LC-MS/MS analysis of 17 Alternaria toxins in urine and fecal samples allowed to gain first insights regarding xenobiotic metabolism and excretion rates. Alternariol (6-10%), alternariol monomethyl ether (AME, 6-7%) and tenuazonic acid (up to 55%) were recovered in urine and fecal samples (9%, 87%, 0.3%, respectively), while perylene quinones administered at comparatively high levels, were either determined at very low levels (up to 0.5% altertoxin I in urine and 15% in feces; 0.2% alterperylenol in urine and 3% in feces) or not at all (altertoxin II, stemphyltoxin III). AME-3-sulfate, which was not present in the administered extract, was determined in urine, representing up to 23% of the AME intake. Critical evaluation of the applied sample preparation protocol and LC-MS/MS analysis revealed interesting preliminary results and information crucial for improving follow-up experiments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.toxlet.2018.10.006 | DOI Listing |
Front Physiol
January 2025
Departamento de Paciente Crítico, Clínica Alemana de Santiago, Santiago, Chile.
Assessing muscle mass in critically ill patients remains challenging. This retrospective cohort study explores the potential of phase angle (PA°) derived from bioelectrical impedance analysis (BIA) as a surrogate marker for muscle mass monitoring by associating it with daily creatinine excretion (DCE), a structural and metabolic muscle mass marker. In 20 ICU patients, we observed a linear relationship between PA° and DCE at initial (S1) and follow-up (S2) points, with Rho values of 0.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, Natal, 59064-741, RN, Brazil.
The COVID-19 pandemic caused by SARS-CoV-2 continues to pose a major challenge to global health. Targeting the main protease of the virus (Mpro), which is essential for viral replication and transcription, offers a promising approach for therapeutic intervention. In this study, advanced computational techniques such as molecular docking and molecular dynamics simulations were used to screen a series of antiviral compounds for their potential inhibitory effect on the SARS-CoV-2 Mpro.
View Article and Find Full Text PDFJ Physiol Sci
January 2025
Department of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan; V-iCliniX Laboratory, Nara Medical University, Kashihara, Nara, Japan. Electronic address:
In humans, uric acid is an end-product of purine metabolism. Urate excretion from the human kidney is tightly regulated by reabsorption and secretion. At least eleven genes have been identified as human renal urate transporters.
View Article and Find Full Text PDFJ Hazard Mater
January 2025
College of Biological Engineering, Qingdao University of Science and Technology, Qingdao 266000, China. Electronic address:
The ecological impact of tire wear particles (TWP), a significant source of microplastics pollution, is increasingly concerning, especially given their potential effects on the health of aquatic ecosystems. This study investigates the size-dependent ecotoxicological responses of zebrafish (Danio rerio) to TWP exposure, focusing on physiological, metabolic, and microbial community impacts over a 15-day exposure period followed by a 15-day excretion period. Through integrated analysis of gut microbiome composition, liver transcriptomics, and host physiological markers, we found that smaller TWP particles (< 120 μm) induced oxidative stress, evidenced by increased SOD and MDA levels, and inhibited growth by reducing body mass and gut length.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon-14 (C)-labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!